Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €13.06 EUR
Change Today -0.12 / -0.91%
Volume 304.7K
IPH On Other Exchanges
EN Paris
As of 11:39 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

innate pharma sa (IPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - €17.85
52 Week Low
10/16/14 - €5.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INNATE PHARMA SA (IPH)

Related News

No related news articles were found.

innate pharma sa (IPH) Related Businessweek News

No Related Businessweek News Found

innate pharma sa (IPH) Details

Innate Pharma S.A., a biopharmaceutical company, is engaged in the research and development of pharmaceutical products primarily immunotherapy drug candidates for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it is engaged in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. It has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

99 Employees
Last Reported Date: 03/13/15
Founded in 1999

innate pharma sa (IPH) Top Compensated Officers

Co-Founder, Chairman of Executive Board and C...
Total Annual Compensation: €305.2K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: €214.0K
Executive Vice-President, Senior Advisor Fina...
Total Annual Compensation: €244.5K
Compensation as of Fiscal Year 2013.

innate pharma sa (IPH) Key Developments

Innate Pharma S.A. Presents at French Life Science Days conference, Jun-17-2015

Innate Pharma S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Innate Pharma S.A. Reports Revenue Results for the First Quarter of 2015

Innate Pharma S.A. reported revenue results for the first quarter of 2015. The company reported revenues for the first three months of 2015 amounted to EUR 0.4 million against EUR 0.6 million for the same period in 2014. This revenue is from Innate Pharma's collaboration and licensing agreement with Bristol-Myers Squibb and largely relates to recognition of the upfront payment of 24.9 million euros throughout the expected duration of the clinical trials ongoing at the date of signing the agreement.

AstraZeneca plc and Medimmune Announces Immuno-Oncology Collaboration with Innate Pharma SA

AstraZeneca plc and MedImmune, have entered into a collaboration with Innate Pharma SA to develop Innate's anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanised IgG4 antibody. NKG2A is a checkpoint receptor that inhibits the anticancer functions of Natural Killer (NK) and cytotoxic T-cells. The initial development plan includes: Phase II combination clinical trials with MEDI4736 in solid tumours; multiple Phase II trials planned by Innate to study IPH2201 both as monotherapy and in combination with currently approved treatments across a range of cancers; and the development of associated biomarkers. The combination of IPH2201 with MEDI4736 adds to the broad programme of immuno-oncology combination trials that AstraZeneca and MedImmune have planned and underway. The studies aim to address multiple immune pathways, harnessing AstraZeneca's own extensive pipeline and working in partnership to explore the significant potential of immunotherapies in transforming the way cancer patients are treated. Under the terms of the agreements, AstraZeneca will make an initial payment to Innate of $250 million, which includes the consideration for exclusive global rights to co-develop and commercialise IPH2201 in combination with MEDI4736, as well as access to IPH2201 in monotherapy and other combinations in certain treatment areas. AstraZeneca will pay a further $100 million prior to initiation of Phase III development, as well as additional regulatory and sales-related milestones. AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. The arrangement includes the right for Innate to co-promote in Europe for a 50% profit share in the territory.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPH:FP €13.06 EUR -0.12

IPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation IPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 86.8x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 77.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNATE PHARMA SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at